NCT07220083ClinicalTrials.gov
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants
In brief
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS. Participants are put…
Phase 3286 participants sought309 sites37 countries
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07220083Open this record at ClinicalTrials.govSynced 5 days ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-10-23; recorded start 2026-02-16
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1233 other studies in this databaseCounted from the lead sponsor named in the record (Boehringer Ingelheim)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 296 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 286 participants (target), run at 309 sites, across 37 countries.
How this score is built
- Enrolment24/40
286 participants (target)
- Site count25/25
296 sites
- Country count15/15
40 countries
- Planned duration8/10
Planned over about 36 months
- Sponsor scale10/10
Boehringer Ingelheim has led 1,211 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS. Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine. Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS. Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Focal Segmental Glomerulosclerosis
Eligibility
| Sex | All |
|---|---|
| Ages | 12 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 3 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 286 participants sought |
Sponsor and collaborators
- Boehringer Ingelheim Sponsor
Arms and interventions
- BI 764198 treatmentEXPERIMENTAL
- Placebo treatmentEXPERIMENTAL
Interventions
- Drug BI 764198
BI 764198
- Drug Placebo
Placebo matching BI 764198
Outcome measures
Primary outcome
Relative change in 24-hour UPCR (measured in mg/g) from baseline to Week 104
24-hour urinary protein-to-creatinine ratio (24-hr UPCR)
Time frame Baseline and Week 104
Secondary outcome
Key secondary endpoint: Absolute change in eGFRcys in mL/min/1.73m2 from baseline to Week 104
Estimated glomerular filtration rate based on serum cystatin C (eGFRcys)
Time frame Baseline and Week 104
Secondary outcome
Key secondary endpoint: Treatment response, defined as 24-hr UPCR <1000 mg/g at Week 104
24-hour urinary protein-to-creatinine ratio (24-hr UPCR)
Time frame At Week 104
Secondary outcome
Treatment response, defined as 24-hr UPCR <1000 mg/g and eGFRcys ≥85% vs. baseline at Week 104 and no treatment failure between randomisation and Week 104 (combined or multi-component endpoint)
Treatment failure defined as one or more of the following: * Use of rescue therapy (treatment escalation) * worsening or severely active disease is defined when the Investigator determines that the randomised treatment regimen has failed and requires treatment escalation newly introduced during the trial (treatment escalation means either initiation of a new medication, or increasing the dose, or target peak or trough level of selected co-medications). * intensification of immunosuppressive medications used at screening. Therapies that are considered include: * calcineurin inhibitors * azathioprine, mycophenolate mofetil * cyclophosphamide, chlorambucil * glucocorticoids: prednisolone dose escalated to a dose of ≥20 mg/d (oral or intravenous) or equivalent for more than 14 days for treatment of kidney disease * Presence of any of the events: * End-stage kidney disease (defined as initiation of chronic renal replacement therapy or receipt of a kidney transplant) * Death
Time frame At Week 104
Secondary outcome
Complete remission, defined as 24-hr UPCR <300 mg/g at Week 104
24-hour urinary protein-to-creatinine ratio (24-hr UPCR)
Time frame At Week 104
Secondary outcome
Change from baseline across disease-specific clinical outcome assessment (COA) NS-SIM-PRO at Week 104
The nephrotic syndrome swelling impact measure (NS-SIM-PRO) has 23 items covering physical function (e.g. mobility), physical symptoms (e.g. fatigue, nausea), and essential function (e.g. vision) impacts identified as being important aspects of participants' experiences with nephrotic-syndrome related swelling. It is expected that all item responses will be combined to generate a single score representing overall swelling impact. The score ranges from 0 up to 4 (0 = never, 1 = almost never, 2 = sometimes, 3 = often, 4 = almost always). A lower score on any of the NS-SIM-PRO subscales indicate a better quality of life.
Time frame Baseline and Week 104
Secondary outcome
Change from baseline across clinical outcome assessment (COA) KDQOL-36 at Week 104
Kidney disease quality of life 36-item short form survey (KDQOL-36) assessing the health-related quality of life (HRQOL) in adult participants with kidney disease. It combines the generic SF-12 Health Survey with additional items specifically relevant to kidney disease. Key Components: * SF-12 Health Survey: Includes 12 items that measure physical and mental health, providing a broad overview of the patient's general health status. * Burden of Kidney Disease: This subscale (4 items) assesses how much kidney disease interferes with daily life and causes frustration. * Symptoms/Problems: This subscale (12 items) evaluates the frequency and severity of symptoms related to kidney disease, such as pain, fatigue, and sleep disturbances. * Effects of Kidney Disease: This subscale (8 items) measures the impact of kidney disease on daily activities and overall well-being. The score ranges from 0 up to 6 and a higher score on most of the KDQOL-36 subscales indicate a better quality of life.
Time frame Baseline and Week 104
Dates
| Start date | February 16, 2026 (actual) |
|---|---|
| Primary completion | December 27, 2028 (estimated) |
| Completion | January 24, 2029 (estimated) |
| First posted | October 23, 2025 (actual) |
| Last updated | November 13, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | November 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
255 sites are recruiting
Argentina
| Facility | City | State or region | Status |
|---|---|---|---|
| Terapia Renal Domiciliaria | Buenos Aires | Recruiting | |
| Hospital Italiano de Buenos Aires | CABA | Recruiting | |
| CEMIC | CABA | Recruiting | |
| Centro Medico Dra Laura Maffei | Ciudad Autonoma Buenos Aires | Recruiting | |
| Clinica Privada Velez Sarfield | Córdoba | Recruiting | |
| Hospital Universitario Austral | Pilar | Recruiting | |
| CardioAlem Investigaciones | San Isidro | Recruiting | |
| Centro Integral de Medicina Respiratoria - CIMER | San Miguel de Tucumán | Not yet recruiting | |
| Grupo MIT - Medicina Interdisciplinaria y Trasplantes | Santa Fe | Not yet recruiting |
Australia
| Facility | City | State or region | Status |
|---|---|---|---|
| Royal Adelaide Hospital | Adelaide | South Australia | Recruiting |
| Concord Repatriation General Hospital | Concord | New South Wales | Not yet recruiting |
| Royal Brisbane and Women's Hospital | Herston | Queensland | Recruiting |
| Nepean Hospital | Kingswood | New South Wales | Recruiting |
| St George Hospital | Kogarah | New South Wales | Recruiting |
| Royal Melbourne Hospital | Parkville | Victoria | Recruiting |
| Griffith Health | Southport | Queensland | Recruiting |
| Sunshine Hospital | St Albans | Victoria | Recruiting |
| The Children's Hospital at Westmead | Westmead | New South Wales | Not yet recruiting |
Belgium
| Facility | City | State or region | Status |
|---|---|---|---|
| AZORG Ziekenhuis | Aalst | Recruiting | |
| UZ Leuven | Leuven | Recruiting | |
| Centre Hospitalier Universitaire de Liège | Liège | Recruiting |
Brazil
| Facility | City | State or region | Status |
|---|---|---|---|
| Synvia | Campinas | Recruiting | |
| Universidade Federal do Ceara | Fortaleza | Recruiting | |
| Hospital de Clinicas de Porto Alegre | Porto Alegre | Recruiting | |
| Hospital das Clinicas da Universidade Federal de Pernambuco | Recife | Recruiting | |
| Centro de Pesquisa Clínica de Nefrologia do ICHC | São Paulo | Recruiting | |
| Instituto da Crianca e do Adolescente | São Paulo | Recruiting | |
| Fundacao Oswaldo Ramos (Hospital do Rim) | São Paulo | Recruiting |
Canada
| Facility | City | State or region | Status |
|---|---|---|---|
| Victoria Hospital (LHSC) | London | Ontario | Recruiting |
| Maisonneuve-Rosemont Hospital | Montreal | Quebec | Recruiting |
| Montreal General Hospital - McGill University Health Centre | Montreal | Quebec | Recruiting |
| Toronto General Hospital | Toronto | Ontario | Recruiting |
| BC Children's Hospital | Vancouver | British Columbia | Not yet recruiting |
China
| Facility | City | State or region | Status |
|---|---|---|---|
| The First Affiliated Hospital of Baotou Medical College | Baotou | Recruiting | |
| Peking University First Hospital | Beijing | Recruiting | |
| Beijing Tsinghua Changgung Hospital | Beijing | Recruiting | |
| The Second Hospital of Jilin University | Changchun | Recruiting | |
| The Second Xiangya Hospital Of Central South University | Changsha | Recruiting | |
| West China Hospital, Sichuan University | Chengdu | Recruiting | |
| Sichuan Provincial People's Hospital | Chengdu | Recruiting | |
| Guangdong Provincial People's Hospital | Guangzhou | Recruiting | |
| The First Affiliated Hospital, Zhejiang University | Hangzhou | Recruiting | |
| Lanzhou University Second Hospital | Lanzhou | Recruiting | |
| The First Affiliated Hospital of Nanchang University | Nanchang | Recruiting | |
| Zhongda Hospital Southeast University | Nanjing | Recruiting | |
| The First People's Hospital of Nanning | Nanning | Recruiting | |
| The First Affiliated Hospital of Guangxi Medical University | Nanning | Recruiting | |
| The First Affiliated Hospital of Ningbo University | Ningbo | Recruiting | |
| Ruijin Hospital Shanghai Jiao Tong University School of Medicine | Shanghai | Recruiting | |
| Shanghai General Hospital | Shanghai | Recruiting |
259 further sites are listed in the registry record.
Study documents
No documents are linked in this registry record.
Changes over time
- November 13, 2026
Site removed
6 sites removed (309 total)
315309
- November 5, 2026
Site removed
1 site removed (315 total)
316315
- October 14, 2026
Site added
5 sites added (316 total)
311316
- September 30, 2026
Site added
4 sites added (311 total)
307311
- September 17, 2026
Site removed
2 sites removed (307 total)
309307
- September 8, 2026
Site added
3 sites added (309 total)
306309
- August 20, 2026
Site added
4 sites added (306 total)
302306
- August 6, 2026
Site added
6 sites added (302 total)
296302